Targeted drug tested for tough cancers with specific genetic flaw
NCT ID NCT04439318
Summary
This study is testing a drug called trametinib for people with advanced cancers that have a specific genetic change called an NF1 mutation. The drug works by blocking proteins that these cancer cells may need to grow. Researchers want to see if trametinib can shrink these tumors or stop them from getting worse in patients whose cancer has not responded to other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.